Skip to content
OpenCapital
Get started

BioXcel Therapeutics, Inc. BTAI Q3 2025 earnings

Reported November 12, 2025 · Before market open

Revenue$98.0KMiss by $71.0K
EPS-$2.18Miss by $0.64
Revenue estimate$169.0K
EPS estimate-$1.54

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$423.1K
EPS estimate-$0.42

Versus estimates

Revenue

Q1 2026$206.0KMiss by $175.5KQ4 2025$256.0KBeat by $104.5K
Q3 2025$98.0KMiss by $71.0K
Q2 2025$120.0KMiss by $137.5KQ1 2025$168.0KMiss by $182.0KQ4 2024$366.0KMiss by $352.3K

Diluted EPS

Q1 2026-$0.54Miss by $0.01Q4 2025-$0.58Miss by $0.24
Q3 2025-$2.18Miss by $0.64
Q2 2025-$2.45Miss by $0.15Q1 2025-$1.50Beat by $1.22Q4 2024-$3.57Beat by $0.79

Ask the moment BioXcel Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did BioXcel Therapeutics, Inc. report Q3 2025 earnings?
BioXcel Therapeutics, Inc. (BTAI) reported Q3 2025 earnings on November 12, 2025 before market open.
What were BioXcel Therapeutics, Inc.'s Q3 2025 revenue and EPS?
BioXcel Therapeutics, Inc. reported revenue of $98.0K and eps of $-2.18 for Q3 2025.
Did BioXcel Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $169.0K by $71.0K. EPS missed the consensus estimate of $-1.54 by $0.64.
How did BioXcel Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 54.2% from $214.0K a year earlier and eps grew 57.4% from $-5.12.
Where can I find BioXcel Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-108840) and the 10-Q periodic report (0001104659-25-109880) directly on SEC EDGAR. The filing index links above go to sec.gov.